Cinclus Pharma
19.898
SEK
+0.16 %
CINPHA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
+0.16%
-23.4%
-34.97%
-
-
-
-
-
-38.97%
cincluspharma.com/sv
Cinclus Pharma is a Swedish pharmaceutical company in the clinical phase. The company is active in the development of molecules for the treatment of acid-related diseases. The company's leading drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and has its headquarters in Stockholm.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CINPHA
Daily low / high price
19.116 / 20.27
SEK
Market cap
926.01M SEK
Turnover
1.02M SEK
Volume
51K
Financial calendar
Annual report
20.02.2025
Interim report
19.05.2025
General meeting
22.05.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Trill Impact Ventures Pharma 1 | 8.0 % | 8.0 % |
| Fjärde AP-fonden | 7.9 % | 7.9 % |
| Futur Pension | 6.4 % | 6.4 % |
| Linc AB | 5.0 % | 5.0 % |
| Peter Unge | 4.4 % | 4.4 % |
| Kjell Andersson | 4.1 % | 4.1 % |
| Mikael Dahlströms Dödsbo | 4.0 % | 4.0 % |
| Movestic Life Insurance AB | 3.8 % | 3.8 % |
| Lennart Hansson through company | 2.3 % | 2.3 % |
| Irrus Investments | 2.1 % | 2.1 % |
ShowingAll content types
Redeye: Cinclus Pharma Q3 - Progress in preparations ahead of pivotal study
Interim Report January – September 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools